Menu
Home / Guides / Mounjaro vs. Zepbound
One medicine. Two labels.
Mounjaro vs. Zepbound (2026): Same Tirzepatide, Different Approvals and Prices
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated
Both are Lilly’s tirzepatide: Mounjaro (type 2 diabetes) is $499 a month at LillyDirect, Zepbound (weight, sleep apnea) $299–$449 by dose (November 1, 2026). Zepbound’s $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide is neither brand and isn’t FDA-approved; at NexLife it’s $115 a month on the 12-month plan, or $129 month to month.
$115/mo on 12 months, every dosePrice Match Guarantee†
- Mounjaro: type 2 diabetes from age 10, plus a heart-risk use
- Zepbound: weight loss and sleep apnea, for adults
- Same strengths: 2.5 mg to start, up to 15 mg weekly

$115/mo on a 12-month plan, all-inclusive, same price at every dose
Or $129/mo month to month
Brand-name Zepbound, for weight: $299 to $449 a month at LillyDirect, by dose; $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $115 | $1,380 |
| 6-month | $119 | $1,428 |
| 3-month | $125 | $1,500 |
| Month to month | $129 | $1,548 |
Month to month costs $168 more over 12 months than the 12-month plan. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout ($375, $714 or $1,380), and only if you’re prescribed. Plans renew until you cancel.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Compounded tirzepatide isn’t FDA-approved, isn’t Mounjaro or Zepbound, and wasn’t studied in Lilly’s trials.
Quick answer
Mounjaro vs. Zepbound at a glance: uses, cost and coverage
| Question | Answer |
|---|---|
| Is it the same medicine? | Yes: both are tirzepatide, made by Eli Lilly, in the same strengths, 2.5 mg to 15 mg |
| What is Mounjaro approved for? | Type 2 diabetes, in adults and children 10 and older, and lowering heart risk in adults with type 2 diabetes at high risk |
| What is Zepbound approved for? | Reducing excess weight and keeping it off in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea with obesity |
| Which is for weight loss? | Zepbound. Mounjaro for weight alone is off-label |
| What does each cost self-pay? | Zepbound: $299 to $449 a month at LillyDirect, by dose; the $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699. Mounjaro: $499 at every dose |
| Who covers it? | Plans and Medicare Part D can cover Mounjaro for type 2 diabetes and Zepbound for sleep apnea; weight-loss coverage varies by plan |
From the Mounjaro and Zepbound labels, LillyDirect, CMS and Medicare.gov, checked November 15, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Same tirzepatide, 2.5 mg to 15 mg: Mounjaro is approved for type 2 diabetes, Zepbound for weight loss and sleep apnea.
- Mounjaro for weight loss is off-label. Its label covers type 2 diabetes from age 10, plus a heart-risk use.
- Mounjaro self-pay: $499 a month at LillyDirect, at every dose, for an approved use (checked Nov. 12, 2026).
- Zepbound self-pay: $299 to $449 a month by dose; the $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699.
- Coverage follows the label: plans can cover Mounjaro for type 2 diabetes and Zepbound for sleep apnea; weight coverage varies.
- Compounded tirzepatide is neither brand and isn’t FDA-approved; at NexLife it’s $115 a month on the 12-month plan.
At a glance
How are Mounjaro and Zepbound different?
The medicine is the same: tirzepatide, made by Eli Lilly. The approvals, the ages, what Lilly sells and who pays are not.
| Mounjaro | Zepbound | |
|---|---|---|
| The medicinemade by Eli Lilly | Tirzepatide, a weekly shot that activates GIP and | Tirzepatide, a weekly shot |
| FDA-approved forlabels checked November 1, 2026 | Type 2 diabetes in adults and children 10 and older. Lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk | Reducing excess weight and keeping it off, in adults with obesity or with overweight and a weight-related condition. Moderate to severe obstructive sleep apnea in adults with obesity |
| WhenFDA approval | 2022. Children added December 2025; heart use added August 2026 | November 2023 for weight; December 2024 for sleep apnea |
| Ages | Adults, and children 10 and older (up to 10 mg) | Adults only |
| Dosesboth start at 2.5 mg | 2.5 mg steps, at least 4 weeks apart, only if blood sugar needs more control; up to 15 mg | Stay on 5, 10 or 15 mg for weight, or 10 or 15 mg for sleep apnea; up to 15 mg |
| Formson both labels | Single-dose pen or vial, a 4-dose vial, a 4-dose KwikPen | The same four |
| At LillyDirectchecked Nov. 12, 2026 | Single-dose pens: $499 a month at every dose, for an approved use, age 18 and up | KwikPen or single-dose vials: $299 to $449 a month by dose; $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699 |
| Main trialfrom the labels | SURPASS-2 (2021) A1c down 2.0 to 2.3 points at 40 weeks, vs. 1.9 on Ozempic 1 mg | SURMOUNT-1 (2022) weight down 15.0% to 20.9% at 72 weeks, vs. 3.1% on placebo |
| Common side effects5 to 15 mg, vs. placebo | Nausea 12% to 18% (4%), diarrhea 12% to 17% (9%), in diabetes trials | Nausea 25% to 29% (8%), diarrhea 19% to 23% (8%), in weight trials |
| Coverage2026 and 2027 | Plans and Medicare Part D can cover it for type 2 diabetes. Savings card: as little as $25 a fill | Weight coverage varies by plan; Part D can cover it for sleep apnea. Medicare’s Bridge: the KwikPen at $50 a month if you qualify. Pen savings card ends December 31, 2026 |
NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works
Swipe the table sideways to see every column.
From the Mounjaro and Zepbound labels (both revised August 2026), LillyDirect and Lilly’s savings terms, CMS and Medicare.gov, checked November 15, 2026. Side effects come from each label’s own trials, not a head-to-head.
Which fits you
Mounjaro or Zepbound: which one is for you?
Your diagnosis decides it, and your coverage follows. Here are the common situations.
If you have type 2 diabetes
Mounjaro is the tirzepatide approved for it, for adults and children 10 and older. Plans and Medicare drug plans can cover it, and with commercial coverage, Lilly’s savings card can bring a fill to as little as $25.
If you want to lose weight
Zepbound is the one approved for weight loss. Mounjaro for weight would be off-label: Lilly says it isn’t a weight loss drug, and LillyDirect sells it only for an approved use.
If you have sleep apnea and obesity
Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, with 10 or 15 mg as the doses to stay on. Medicare drug plans can cover it for that use.
If cost is the barrier
Self-pay, Zepbound is $299 to $449 a month at LillyDirect, and Mounjaro $499 at every dose. Zepbound’s $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699. The KwikPen and vials cost the same.
If you have Medicare
Part D plans can cover Mounjaro for diabetes and Zepbound for sleep apnea. For weight loss alone, the
GLP-1 Bridge covers the Zepbound KwikPen at $50 a month, if you qualify, through December 31, 2027.If your coverage changes in 2027
Lilly’s Zepbound savings cards end December 31, 2026, their terms say. LillyDirect’s self-pay prices list no end date (November 1, 2026).
Your provider decides. These are starting points, not a plan: what you’re treating, your other conditions and your coverage all count.
Step by step
How do you choose between Mounjaro and Zepbound?
The medicine is the same, so the choice comes down to what you’re treating, what your coverage pays for and what you’d pay yourself.
- Start with your diagnosis. Mounjaro is the tirzepatide approved for type 2 diabetes, in adults and children 10 and older. Zepbound is approved for weight loss and for moderate to severe obstructive sleep apnea in adults with obesity.
- For weight alone, it’s Zepbound. Mounjaro for weight loss would be off-label: Lilly says it isn’t a weight loss drug, and LillyDirect sells it only for an approved use. Plans can deny it for that use.
- Check your coverage. Plans and Medicare Part D can cover Mounjaro for type 2 diabetes and Zepbound for sleep apnea; weight-loss coverage varies by plan. For weight alone, Medicare’s Bridge covers the Zepbound KwikPen at $50 a month, if you qualify.
- Compare the self-pay price. At LillyDirect, Mounjaro is $499 a month at every dose, for an approved use. Zepbound is $299 to $449 by dose; the $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699.
- Expect the same warnings. Both carry the same warnings, including the boxed warning: tirzepatide caused thyroid C-cell tumors in rats. Their trials measured different things, blood sugar for Mounjaro and weight for Zepbound, so the results can’t be set side by side.
- Let your provider decide. Your provider decides, from what you’re treating, your other conditions and your coverage. A switch needs a new prescription, and you take one brand or the other, not both.
Prices were checked Nov. 12, 2026, and your provider decides which brand fits you.
Approvals
When were Mounjaro and Zepbound approved, and what’s changed?
Mounjaro came first, in 2022, for type 2 diabetes. Zepbound followed in November 2023 for weight, and both labels have changed since.
The FDA approves Mounjaro, the first tirzepatide, to improve blood sugar in adults with type 2 diabetes.
The FDA approves Zepbound for chronic weight management in adults with obesity, or overweight with a weight-related condition.
Zepbound becomes the first medicine approved for moderate to severe obstructive sleep apnea, in adults with obesity.
Mounjaro’s label adds children 10 and older with type 2 diabetes, up to 10 mg a week.
Both labels add a warning never to share a KwikPen between patients.
LillyDirect starts selling the Zepbound KwikPen at the vial prices, $299 for the 2.5 mg starting dose.
Mounjaro’s label adds lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk.
Lilly’s Zepbound savings cards end, including the KwikPen self-pay card, their terms say.
Medicare’s
GLP-1 Bridge, which covers the Zepbound KwikPen for weight loss at $50 a month, is set to end.
What each brand name means, and the FAQ on tirzepatide’s names: tirzepatide brand names.
Dosage
Mounjaro vs. Zepbound dosage: are the doses the same?
Mostly: the strengths are the same, and both start at 2.5 mg a week, rising 2.5 mg at a time, at least 4 weeks apart, up to 15 mg. Both labels move everyone to 5 mg after 4 weeks; then Mounjaro’s steps up only if blood sugar needs more control.
| Mounjaro | Zepbound | |
|---|---|---|
| First 4 weeks | 2.5 mg once a week | 2.5 mg once a week |
| Then | 5 mg | 5 mg |
| Each step after thatat least 4 weeks apart | 2.5 mg more, if blood sugar needs more control | 2.5 mg more |
| Doses to stay on | None named: you step up only if blood sugar needs more control | Weight: 5, 10 or 15 mg. Sleep apnea: 10 or 15 mg |
| Highest dose | 15 mg; 10 mg for children | 15 mg |
| Strengthssingle-dose pens or vials | 2.5, 5, 7.5, 10, 12.5 and 15 mg | The same six |
| 4-dose KwikPen or vial2.4 mL | Four weekly doses of 2.5 to 15 mg | The same |
Swipe the table sideways to see every column.
From each label’s dosing section, both revised August 2026, read November 1, 2026. Your provider sets your dose; this isn’t a dosing plan.
For Zepbound, 2.5 mg is a starter. Its label and LillyDirect say it isn’t approved as a dose to stay on. Mounjaro’s label names no dose to stay on.
KwikPen or vial? The medicine is the same; the device differs. One KwikPen holds a month’s four doses and needs pen needles, and vials need a needle and syringe, LillyDirect says. Day to day: tirzepatide pen vs. vial.
Trials
What did the Mounjaro and Zepbound trials find?
Each brand was tested for its own job: Mounjaro lowered A1c by 2.0 to 2.3 points in type 2 diabetes. Zepbound cut weight by 15.0% to 20.9% on average, vs. 3.1% on placebo, and sleep apnea breathing events by 50.7% to 58.7%.
| Trial | Who, and for how long | What it found |
|---|---|---|
| SURPASS-2 (2021)Mounjaro | 1,879 adults with type 2 diabetes on metformin, 40 weeks, against Ozempic 1 mg | A1c fell 2.0 to 2.3 points on 5 to 15 mg, vs. 1.9 on Ozempic; weight fell 7.6 to 11.2 kg, vs. 5.7 kg |
| SURMOUNT-1 (2022)Zepbound, weight | 2,539 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes, 72 weeks, against placebo | Weight fell 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg, vs. 3.1% on placebo |
| SURMOUNT-OSA (2024)Zepbound, sleep apnea | 469 adults with obesity and moderate to severe sleep apnea, 52 weeks, in two trials, without and with PAP | Breathing events (AHI) fell by 25.3 and 29.3 an hour (50.7% and 58.7%), vs. 5.3 and 5.5 on placebo |
Swipe the table sideways to see every column.
Results from the Mounjaro and Zepbound labels (section 14, revised August 2026), read November 15, 2026. The years are when each trial was published or first reported.
Don’t set them side by side. The trials enrolled different people and measured different things, blood sugar in one and weight or breathing in the others, so their numbers aren’t one medicine’s effect in two forms.
These trials studied FDA-approved Mounjaro and Zepbound; compounded tirzepatide wasn’t studied.
Cost
Mounjaro or Zepbound: which is cheaper?
Zepbound, if you pay yourself and refill on time: LillyDirect charges $299 to $449 a month for it, by dose, and $499 for Mounjaro at every dose (checked November 15, 2026). Zepbound’s $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699. With coverage, either can cost as little as $25 a fill.
| Weekly dose | Mounjaro, pens | Zepbound, refilled within 45 days | Zepbound, refill after 45 days |
|---|---|---|---|
| 2.5 mg | $499 | $299 | $299 |
| 5 mg | $499 | $399 | $399 |
| 7.5 mg | $499 | $449 | $499 |
| 10 mg | $499 | $449 | $699 |
| 12.5 mg | $499 | $449 | $699 |
| 15 mg | $499 | $449 | $699 |
Swipe the table sideways to see every column.
LillyDirect self-pay prices, checked Nov. 15, 2026. A month is four Mounjaro pens, or one Zepbound KwikPen or four vials (28 days). Medication only.
Savings cards and other prices
| Mounjaro savings card | As little as $25 for up to a 3-month prescription, if you’re commercially insured and your plan covers Mounjaro. Monthly and annual limits apply, and government beneficiaries can’t use it. |
|---|---|
| Zepbound savings card | For single-dose pens: as little as $25 for a 1-, 2- or 3-month fill if your plan covers them, up to $100 off a month and $1,300 a year; as low as $499 for a month if it doesn’t. It ends December 31, 2026. |
| TrumpRx.gov | Lists Zepbound vials starting at $299, ordered through LillyDirect. |
| Compounded tirzepatide, through NexLife | $115 a month on the 12-month plan, or $129 month to month, at every dose. It’s neither brand, and it isn’t FDA-approved. |
A year at LillyDirect, in 13 four-week fills: $6,487 for Mounjaro, and $5,637 for Zepbound if you step up from 2.5 mg to 7.5 mg or more, with every refill within 45 days.
For weight loss at NexLife, a year of compounded tirzepatide is $1,380 on the 12-month plan, or $1,548 month to month: a different product that isn’t FDA-approved and isn’t a treatment for type 2 diabetes.
Paying less for compounded tirzepatide elsewhere? Our Price Match Guarantee† matches your regular monthly price. Every Zepbound price and its 45-day rule: Zepbound cost without insurance.
Weight-loss denials
Why won’t insurance cover Mounjaro for weight loss?
Because weight loss isn’t one of its FDA-approved uses; prescribing it for weight alone is off-label. Mounjaro’s label covers type 2 diabetes and, since August 2026, heart-risk reduction in adults with type 2 diabetes. Coverage follows the label: Zepbound, the same tirzepatide, is the brand approved for weight loss.
“Mounjaro is not a weight loss drug.”
- Plans decide by diagnosis. Mounjaro’s approved use is type 2 diabetes, and a plan can ask your prescriber to show that diagnosis before it pays.
- Lilly’s own pharmacy asks too. To buy Mounjaro at LillyDirect’s $499, you confirm it was prescribed “for an approved use consistent with the FDA-approved product labeling,” and that you’re 18 or older.
- Medicare doesn’t cover weight loss alone. Medicare drug plans don’t pay for drugs used only for weight loss. The Bridge, for the Zepbound KwikPen, is the exception.
- For weight, the approved tirzepatide is Zepbound. If your plan won’t cover it, you can appeal, or pay $299 to $449 a month at LillyDirect. Zepbound’s $449, from 7.5 mg, needs a refill within 45 days, or it’s $499 to $699.
Denied, or losing coverage? What to do when your plan says no.
Coverage
Do insurance and Medicare cover Mounjaro and Zepbound?
Yes, for some uses: coverage follows the label. Plans and Medicare Part D can cover Mounjaro for type 2 diabetes. Zepbound depends on why it’s prescribed: Part D can cover sleep apnea, and weight-loss coverage varies by plan. Mounjaro for weight loss is off-label.
Mounjaro and Part D
Medicare drug plans can cover Mounjaro for type 2 diabetes. People with type 2 diabetes can’t use the Bridge; their Part D plan may cover a
GLP-1 instead.Zepbound for sleep apnea
Part D plans can cover Zepbound for moderate to severe sleep apnea with obesity, an approved use. People with that diagnosis aren’t eligible for the Bridge.
Zepbound for weight: the Bridge
$50 a month for the KwikPen, not vials or single-dose pens, for people with Part D who qualify, through December 31, 2027. The $50 doesn’t count toward your deductible or out-of-pocket limit.
What changes in 2027
Lilly’s Zepbound savings cards end December 31, 2026. Tirzepatide isn’t on Medicare’s price negotiation lists for 2027 or 2028.
Employer and Medicare changes on January 1:
Switching
Can you switch from Mounjaro to Zepbound?
Yes, with a new prescription for Zepbound. Both are tirzepatide in the same strengths, and your provider decides your dose.
What a switch follows
A change in what’s being treated or covered: weight rather than blood sugar, a sleep apnea diagnosis, or a plan that pays for one brand and not the other.
Your dose
The two come in the same strengths, and neither label describes moving between them. Your provider decides whether you stay at your dose or step back.
One at a time
Zepbound’s label says not to use it with other tirzepatide products or any
GLP-1 receptor agonist, so you take one or the other.Diabetes medicines
With insulin or a sulfonylurea, both labels warn that low blood sugar is more likely; both say lowering those doses can reduce the risk. Your provider plans it with you.
Going the other way? A type 2 diabetes diagnosis can move you from Zepbound to Mounjaro, the brand approved for it, with a new prescription.
What changes when you switch, and what doesn’t
| Mounjaro | Zepbound | On a switch | |
|---|---|---|---|
| Medicine and strengths | Tirzepatide, 2.5 mg to 15 mg | Tirzepatide, 2.5 mg to 15 mg | The same medicine; your provider sets the dose |
| Approved for | Type 2 diabetes, in adults and children 10 and older; lowering heart risk in some adults with type 2 diabetes | Weight loss in adults; moderate to severe obstructive sleep apnea in adults with obesity | Changes: the diagnosis on the prescription decides the brand |
| LillyDirect self-pay, a month | $499 at every dose, as single-dose pens, only for an approved use | $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg with a refill within 45 days; otherwise $499 or $699 | Changes. Zepbound’s KwikPen and vials cost the same |
| Lilly’s savings card | As little as $25 with commercial coverage for type 2 diabetes | As little as $25 with coverage of the single-dose pen; the card ends Dec. 31, 2026 | Changes: each brand has its own card |
| Medicare | Part D plans can cover it for type 2 diabetes | The Bridge: the KwikPen for $50 a month for weight, if you qualify, through Dec. 31, 2027 | Changes. The Bridge excludes people with type 2 diabetes |
| Taking both | Mounjaro is tirzepatide | Its label: not with other tirzepatide products or any | One or the other, never both |
LillyDirect’s Mounjaro and Zepbound pages, its Mounjaro purchase terms and Lilly’s Zepbound savings card terms, read Nov. 15, 2026; the Mounjaro card from Lilly’s Mounjaro site and Medicare’s Bridge rules from Medicare.gov, read Nov. 1, 2026; uses from the labels. Not trial data.
Comparing other weekly diabetes shots? See Trulicity vs. tirzepatide.
In their words
Mounjaro vs. Zepbound: what do Zepbound’s label and Medicare say?
Three lines, word for word: Zepbound’s approved use, its rule on other tirzepatide products, and Medicare on coverage by diagnosis.
Zepbound’s label words its weight-loss use this way, while Mounjaro’s names type 2 diabetes, so coverage and LillyDirect treat the two brands differently.
“to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, section 1 (revised August 2026)
Both brands are tirzepatide, so a switch means one or the other, not both at once.
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, section 1
On Medicare, coverage follows the diagnosis: Part D plans can cover Mounjaro for type 2 diabetes and Zepbound for sleep apnea, outside the $50 Bridge.
“You aren’t eligible for the Medicare GLP-1 Bridge, because your Medicare drug plan should cover GLP-1 medications to treat these conditions.”
Medicare.gov (Centers for Medicare & Medicaid Services), Weight loss drugs, on people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease
Side effects
What side effects and warnings do Mounjaro and Zepbound carry?
Mounjaro and Zepbound carry the same warnings and the same kinds of side effects, including nausea, diarrhea, vomiting, constipation, indigestion and abdominal pain. Zepbound’s label shows higher rates, from 72-week trials in people with obesity rather than 40-week trials in type 2 diabetes.
| Side effect | Mounjaro 5 / 10 / 15 mg | Zepbound 5 / 10 / 15 mg |
|---|---|---|
| Nausea | 12 / 15 / 18% (placebo 4%) | 25 / 29 / 28% (placebo 8%) |
| Diarrhea | 12 / 13 / 17% (9%) | 19 / 21 / 23% (8%) |
| Vomiting | 5 / 5 / 9% (2%) | 8 / 11 / 13% (2%) |
| Constipation | 6 / 6 / 7% (1%) | 17 / 14 / 11% (5%) |
| Indigestiondyspepsia | 8 / 8 / 5% (3%) | 9 / 9 / 10% (4%) |
| Abdominal pain | 6 / 5 / 5% (4%) | 9 / 9 / 10% (5%) |
Swipe the table sideways to see every column.
Each label’s placebo-controlled trials: Mounjaro’s in type 2 diabetes (40 weeks), Zepbound’s in obesity or overweight (72 weeks). Labels read November 15, 2026.
- The boxed warning. In rats, tirzepatide caused thyroid C-cell tumors; whether it does in people isn’t known. Neither brand is for anyone with a personal or family history of medullary thyroid carcinoma (MTC), or anyone with MEN 2.
- Also not for anyone with a serious allergy to tirzepatide or the product’s ingredients. Neither brand is recommended with severe gastroparesis, both labels add.
- Serious risks on both labels: pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach reactions, allergic reactions, low blood sugar with insulin or a sulfonylurea, diabetic eye complications, and breathing in stomach contents under anesthesia.
- Sudden vision loss. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare optic nerve problem that can cause sudden, painless vision loss in one eye; call your provider right away if that happens (FDA).
- Birth control pills. Both labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.
- Pregnancy. Zepbound’s label says to stop when a pregnancy is recognized, since weight loss offers no benefit then and may harm the baby. Mounjaro’s says to use it only if the benefit justifies the risk.
Get care right away for stomach pain that’s severe and won’t ease, with or without vomiting, since the labels say to stop if pancreatitis is suspected; a lump in your neck, hoarseness or trouble swallowing; or signs of a serious allergic reaction. Never share a KwikPen, both labels say. Questions? Call or text
Compounded
How is compounded tirzepatide different from Mounjaro and Zepbound?
A pharmacy prepares it for one person’s prescription, Lilly doesn’t make it, and it isn’t FDA-approved.
- Not Lilly’s. A state-licensed 503A pharmacy prepares it for one patient’s prescription.
- Not FDA-approved. The FDA doesn’t check a compounded drug’s safety, effectiveness or quality before it’s sold, its compounding Q&A says.
- Not studied. SURPASS and SURMOUNT tested Mounjaro and Zepbound, not compounded tirzepatide.
- Prescribed for a reason. A licensed provider prescribes it only when it offers a significant difference for you.
The rules, and when it’s legal: is compounded tirzepatide legal? Side by side with Zepbound: compounded vs. brand-name tirzepatide.
At NexLife
What should you know before choosing compounded tirzepatide at NexLife?
Compounded tirzepatide isn’t FDA-approved, isn’t a treatment for type 2 diabetes and doesn’t replace Mounjaro. NexLife doesn’t offer Mounjaro or Zepbound and doesn’t bill insurance. If a licensed provider prescribes it, it’s $115 a month on the 12-month plan or $129 month to month, at every dose.
If Zepbound doesn’t fit your coverage or budget for weight loss, here’s what compounded tirzepatide comes with at NexLife. It isn’t a treatment for type 2 diabetes and doesn’t replace Mounjaro or your diabetes care.
One price at every dose
$115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months, or $129 month to month, from your first dose to your highest. No membership fee.
A licensed provider decides
Your health history is reviewed online, following your state’s rules. You’re prescribed only if it’s right for you; if you aren’t, you pay nothing for medication.
Two named pharmacies
Absolute Pharmacy in Lutz, FL, or Boudreaux’s New Drug Store in Lake Charles, LA, both state-licensed 503A pharmacies, fill your prescription, and shipping is free and expedited.
Care between refills
A nutrition plan, a 1:1 coaching call and a provider who follows your dose. Real people answer 24/7 at
(949) 818-8000 ; physicians answer medical questions during clinical hours.Ways to pay
NexLife takes HSA and FSA cards and provides a letter of medical necessity if your plan asks for one; Affirm, Klarna or Afterpay are offered at checkout. With Medicare, you can pay for yourself.
Price Match Guarantee†
Switching from another licensed provider who charges less for compounded tirzepatide? Send a receipt from the last 60 days and we match your regular monthly price. Not for Medicare, Medicaid or TRICARE members.
What NexLife doesn’t offer: Mounjaro or Zepbound. Its providers prescribe compounded tirzepatide and semaglutide only, and NexLife doesn’t bill insurance, so if your plan covers a brand for you, that may cost less. NexLife has 4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026), and is LegitScript-certified.
Vial math
How many units is your tirzepatide dose?
Your tirzepatide dose in units depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator.
Loved by our members
Real stories from NexLife members about their care and service.
A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.
★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗
★★★★★Read on Trustpilot ↗
“So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”
April
★★★★★Read on Trustpilot ↗
“Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”
Ethan B.
★★★★★Read on Trustpilot ↗
“That’s a real site with good prices and plans!”
Estefany L.
★★★★★Read on Trustpilot ↗
“Affordable, quick and easy. They could not have made it a smoother less stressful experience.”
Andisheh K.
★★★★★Read on Trustpilot ↗
“Great communication. Easy to work with. They work to set you up for success.”
Anthony C.
★★★★★Read on Trustpilot ↗
“Fast delivery and easy to get a hold of when needing to talk with someone!”
Browneyes
★★★★★Read on Trustpilot ↗
“Great service and excellent communication!”
Gabrielle D.
★★★★★Read on Trustpilot ↗
“Easy and pricing not bad! Customer service was helpful in answering my questions.”
Lyndy T.
★★★★★Read on Trustpilot ↗
“Good experience, great team”
Mai S.
★★★★★Read on Trustpilot ↗
“Great communciation and was fast and reliable”
Kiki
★★★★★Read on Trustpilot ↗
“Very happy so far”
Tammy E.
★★★★★Read on Trustpilot ↗
“Fast service great communication!! Willing to work with you!”
Bon
Names are shortened for privacy. Reviews are members’ opinions, not medical advice.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Mounjaro vs. Zepbound: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Is Mounjaro or Zepbound cheaper without insurance?
Zepbound, with refills within 45 days. LillyDirect charges $299 to $449 a month by dose, vs. $499 for Mounjaro at every dose (November 1, 2026). Later refills cost $499 to $699 from 7.5 mg. For weight loss, compounded tirzepatide, neither brand and not FDA-approved, is $115 a month at NexLife on the 12-month plan, or $129 month to month.
How much is Mounjaro without insurance?
$499 a month at LillyDirect, at every dose from 2.5 mg to 15 mg (checked Nov. 15, 2026). That buys four single-dose pens, a 28-day supply. To pay that price, you confirm Mounjaro was prescribed for an approved use, which means type 2 diabetes, and that you’re 18 or older. A year, in 13 four-week fills, is $6,487. Zepbound, Lilly’s weight-loss tirzepatide, is $299 to $449 a month there by dose, with refills within 45 days.
Does LillyDirect sell Mounjaro for weight loss?
No. LillyDirect’s self-pay terms say you must be prescribed Mounjaro for an approved use consistent with its FDA label, which means type 2 diabetes, and be 18 or older. Lilly’s weight-loss tirzepatide is Zepbound: $299 to $449 a month there by dose with refills within 45 days, against $499 for Mounjaro at every dose (checked Nov. 15, 2026).
Why does insurance cover Mounjaro but not Zepbound?
Coverage follows each brand’s approved use. Mounjaro’s is type 2 diabetes, which plans and Medicare drug plans can cover. Zepbound’s weight-loss use is one Medicare drug plans don’t cover (outside the $50 Bridge) and employer plans may exclude, though Part D can cover Zepbound for sleep apnea.
Can a doctor prescribe Mounjaro instead of Zepbound for weight loss?
It would be off-label: Mounjaro isn’t FDA-approved for weight loss, and Lilly says it isn’t a weight loss drug. Plans can deny it for that use, and LillyDirect’s $499 offer requires a prescription for an approved use. For weight, the approved tirzepatide is Zepbound.
Can I switch from Mounjaro to Zepbound at the same dose?
Your provider decides. Both are tirzepatide in the same six strengths, but neither label describes moving between them. You’ll need a new prescription for Zepbound, and its label says not to use it with other tirzepatide products, so you take one or the other.
Does Medicare cover Mounjaro or Zepbound in 2026?
For approved uses, Part D plans can cover Mounjaro for type 2 diabetes and Zepbound for sleep apnea. For weight loss, the Medicare
Can children take Mounjaro or Zepbound?
Mounjaro, for type 2 diabetes from age 10: its label added children 10 and older in December 2025, with a top dose of 10 mg a week. Zepbound is for adults; its label says safety and effectiveness in children haven’t been established.
Do Mounjaro and Zepbound come in vials and KwikPens?
Both labels list the same four forms: single-dose pens, single-dose vials, a 4-dose vial and a 4-dose KwikPen. LillyDirect sells Zepbound as the KwikPen or single-dose vials for self-pay, and Mounjaro as single-dose pens (checked Nov. 15, 2026). KwikPen needles and vial syringes are bought separately.
Do Mounjaro and Zepbound have the same side effects?
The same kinds and the same warnings, at different rates. At 15 mg, nausea affected 18% in Mounjaro’s diabetes trials (4% on placebo) and 28% in Zepbound’s weight trials (8%), which enrolled different people. These trials studied FDA-approved Mounjaro and Zepbound; compounded tirzepatide wasn’t studied.
Is Zepbound stronger than Mounjaro?
No: both are tirzepatide in the same strengths. Their trials measured different things: blood sugar in SURPASS-2 (2021), and weight in SURMOUNT-1 (2022), where 15 mg of Zepbound averaged 20.9% loss at 72 weeks vs. 3.1% on placebo. These trials studied FDA-approved Mounjaro and Zepbound; compounded tirzepatide wasn’t studied.
What changes if I switch from Mounjaro to Zepbound?
The approved use, the coverage, the savings card and the price, not the medicine. Both are tirzepatide from 2.5 mg to 15 mg, but Zepbound needs its own prescription, and your provider sets the dose. At LillyDirect, Mounjaro is $499 a month at every dose; Zepbound is $299 to $449 by dose with refills within 45 days, or $499 to $699 (checked Nov. 15, 2026).
Is the Zepbound savings card ending?
Yes. Lilly’s Zepbound savings cards, including the KwikPen self-pay card, end December 31, 2026, their terms say. LillyDirect’s self-pay prices list no end date (checked November 15, 2026). For weight loss with Medicare, the GLP-1 Bridge covers the Zepbound KwikPen at $50 a month, if you qualify, through December 31, 2027.
Is Mounjaro approved to lower heart risk?
Yes, since August 2026, for some adults: Mounjaro’s label now includes lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk. Zepbound is approved for weight loss and for moderate to severe obstructive sleep apnea in adults with obesity.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Labels, Lilly’s Mounjaro site and Medicare figures checked Nov. 1, 2026; LillyDirect’s prices and terms and Lilly’s Zepbound savings terms re-checked Nov. 12, 2026.
- How we checked. Every approval, dose, form, warning and side-effect rate comes from the Mounjaro and Zepbound prescribing information (both revised August 2026), read November 15, 2026, and the trial results from their clinical studies sections. Prices and purchase terms come from LillyDirect and Lilly’s savings terms, and Medicare facts from CMS and Medicare.gov, all checked November 1, 2026; LillyDirect’s prices and purchase terms and Lilly’s Zepbound savings terms were re-checked on Nov. 12, 2026. Zepbound’s approval dates come from the FDA. We list announced prices only. Mounjaro, Zepbound, KwikPen, LillyDirect and Trulicity are trademarks of Eli Lilly and Company, and Ozempic and Wegovy of Novo Nordisk. NexLife isn’t affiliated with either.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
You know which brand does what. Next: a 3-minute check.
A licensed provider decides if compounded tirzepatide is right for you. It’s $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Mounjaro (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
- Zepbound prescribing information (PDF), sleep apnea studies. Read November 15, 2026.
- LillyDirect: Mounjaro self-pay prices. Checked Nov. 15, 2026.
- LillyDirect: Mounjaro self-pay purchase terms. Read Nov. 12, 2026.
- LillyDirect: Zepbound self-pay prices. Checked Nov. 15, 2026.
- Eli Lilly: Zepbound full terms and conditions (savings cards). Read November 15, 2026.
- Eli Lilly: Mounjaro official site and savings card. Checked November 15, 2026.
- TrumpRx.gov: Zepbound vial. Checked November 15, 2026.
- Eli Lilly: Zepbound now available in multi-dose KwikPen (February 23, 2026). As read for our “Will tirzepatide get cheaper?” guide, November 1, 2026.
- FDA: FDA approves new medication for chronic weight management (Zepbound), November 8, 2023. Read November 1, 2026.
- AASM: Zepbound for obstructive sleep apnea, provider fact sheet (2026), citing the FDA’s December 20, 2024 approval. Read November 15, 2026.
- CMS: Medicare
GLP-1 Bridge. Read Nov. 15, 2026. - Medicare.gov: Weight loss drugs (the Medicare
GLP-1 Bridge). Read November 15, 2026. - CMS: Medicare drug price negotiation, negotiated prices for 2027 (fact sheet). Read November 1, 2026.
- CMS: Medicare drug price negotiation, selected drugs for 2028 (fact sheet). Read November 1, 2026.
- SURPASS-2: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med, 2021. Results as stated in Mounjaro’s label.
- Eli Lilly: SURPASS-2 topline results, tirzepatide vs. semaglutide 1 mg (March 4, 2021). Read November 1, 2026.
- PharmaTimes: Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial (June 28, 2021). Read November 1, 2026.
- SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 2022. Results as stated in Zepbound’s label.
- FDA: Compounding and the FDA, questions and answers.
- NexLife: pricing, every plan.